E-viri
Odprti dostop
-
Shimada, Yoshifumi; Kameyama, Hitoshi; Nagahashi, Masayuki; Ichikawa, Hiroshi; Muneoka, Yusuke; Yagi, Ryoma; Tajima, Yosuke; Okamura, Takuma; Nakano, Masato; Sakata, Jun; Kobayashi, Takashi; Nogami, Hitoshi; Maruyama, Satoshi; Takii, Yasumasa; Hayashida, Tetsu; Takaishi, Hiromasa; Kitagawa, Yuko; Oki, Eiji; Konishi, Tsuyoshi; Ishida, Fumio; Kudo, Shin-Ei; Ring, Jennifer E; Protopopov, Alexei; Lyle, Stephen; Ling, Yiwei; Okuda, Shujiro; Ishikawa, Takashi; Akazawa, Kohei; Takabe, Kazuaki; Wakai, Toshifumi
Oncotarget, 11/2017, Letnik: 8, Številka: 55Journal Article
Anti-epidermal growth factor receptor (EGFR) therapy has been found to be more effective against left-sided colorectal cancer (LCRC) than right-sided colorectal cancer (RCRC). We hypothesized that RCRC is more likely to harbor genetic alterations associated with resistance to anti-EGFR therapy and tested this using comprehensive genomic sequencing. A total of 201 patients with either primary RCRC or LCRC were analyzed. We investigated tumors for genetic alterations using a 415-gene panel, which included alterations associated with resistance to anti-EGFR therapy: TK receptors ( , , , , and ), RAS pathway ( , , , , and ), and PI3K pathway ( and ). Patients whose tumors had no alterations in these 12 genes, theoretically considered to respond to anti-EGFR therapy, were defined as "all wild-type", while remaining patients were defined as "mutant-type". Fifty-six patients (28%) and 145 patients (72%) had RCRC and LCRC, respectively. Regarding genetic alterations associated with anti-EGFR therapy, only 6 of 56 patients (11%) with RCRC were "all wild-type" compared with 41 of 145 patients (28%) with LCRC ( = 0.009). Among the 49 patients who received anti-EGFR therapy, RCRC showed significantly worse progression-free survival (PFS) than LCRC ( = 0.022), and "mutant-type" RCRC showed significantly worse PFS compared with "all wild-type" LCRC ( = 0.004). RCRC is more likely to harbor genetic alterations associated with resistance to anti-EGFR therapy compared with LCRC. Furthermore, our data shows primary tumor sidedness is a surrogate for the non-random distribution of genetic alterations in CRC.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.